Drugs / IK-930
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05228015 | Jan 2022 → Aug 2024 | epithelioid hemangioendothelioma, malignant pleural mesothelioma | Ikena Oncology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IK-930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05228015 ↗ |
| Action | Inhibit | “TEAD inhibitor” NCT05228015 ↗ |
| Route | Oral | “administered orally (PO)” NCT05228015 ↗ |